Make sure to speak to your doctor if your side effects do not get better after a few weeks, they may recommend staying on a lower dose for longer, or in some cases, semaglutide may not be the right medication for you
About 40-50,000 patients receive GLP-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors(SGLT-2i) drugs, 84,000 were treated with dipeptidyl peptidase-4 (DPP-4) and more than 200,000 received sulfonylureas, with tracking of major adverse outcomes of all-cause mortality, heart attack, stroke, need for coronary revascularization
Moreover, hypertension resolution was achieved in 23% of those treated with GLP-1 agonists, compared to 11% in the placebo group
Integration with digital health platforms and artificial intelligence-powered disease management systems promises to enhance patient outcomes, medication persistence, and clinical efficacy metrics that could support premium pricing and expanded insurance coverage in developed markets